Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
SWOG Cancer Research Network
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07220187CT.gov Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial | — | Not Yet Recruiting | — | — | — |
NCT06735664CT.gov Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation | — | Recruiting | — | — | — |
NCT05665530CT.gov A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | — | Completed | — | — | — |
NCT05873712CT.gov Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | — | Recruiting | — | — | — |
NCT05388006CT.gov Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | — | Recruiting | — | — | — |
NCT04679012CT.gov Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | — | Recruiting | — | — | — |
NCT04992377CT.gov R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL | — | Unknown | — | — | — |
NCT04799275CT.gov Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04623541CT.gov Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome | — | Active Not Recruiting | — | — | — |
NCT04271956CT.gov Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation | — | Recruiting | — | — | — |
Show 4 more trialsShow fewer
NCT03899337CT.gov A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome | — | Recruiting | — | — | — |
NCT03205046CT.gov A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies | — | Terminated | — | — | — |
NCT02362035CT.gov ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | — | Completed | — | — | — |
NCT02029443CT.gov ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Richter Transformation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prednisone (this asset) | SWOG Cancer Research Network | P3 | BB · 66 |
| Obinutuzumab | Christine Ryan | P2 | BB |
| Venetoclax | Northwestern University | P2 | BB |
| Ibrutinib | City of Hope Medical Center | P2 | BB |
| Rituximab | SWOG Cancer Research Network | P3 | BB |
| Cyclophosphamide | SWOG Cancer Research Network | P3 | BB |
| Pirtobrutinib | SWOG Cancer Research Network | P3 | BB |
| Humax-Cd20 | University of Oxford | P2 | BB |
| Adriamycin | SWOG Cancer Research Network | P3 | BB |
+42 more in the Richter Transformation cohort
Other indications for Prednisone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 74 |
| Diffuse Large B-Cell Lymphoma | — | P4 | BBB · 74 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prednisone in Richter Transformation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prednisone-richter-transformation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →